



Current Agreements

Dealdoc

Equity purchase financing for \$23 million

Alnylam Pharmaceuticals
Genzyme

Mar 26 2014

Equity purchase financing for \$23 million

Companies:	Alnylam Pharmaceuticals Genzyme
Announcement date:	Mar 26 2014
Value, US\$m:	23 : sum of shares
Related contracts:	Co-development, co-marketing, equity purchase and option agreement for ALN-TTRsc and 2 other products

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Mar 26 2014
Type:	Equity purchase Bigbiotech
Industry sectors:	Biotech Pharmaceutical

Financials

Value, US\$m:	23 : sum of shares
----------------------	--------------------

Termsheet

Alnylam Pharmaceuticals has exercised its right to purchase 344,448 unregistered shares of Alnylam's common stock in accordance with the terms of an investor rights agreement between Alnylam and Genzyme, dated January 11, 2014.

These shares became available for purchase by Genzyme as a result of Alnylam's issuance of shares of common stock to Merck in connection with Alnylam's acquisition of Sirna Therapeutics.

Genzyme has the right to purchase additional shares to maintain its ownership percentage of the company's common stock.

On March 25, 2014, Genzyme purchased these additional shares at a purchase price of \$66.88, the closing price of Alnylam's stock that day, and paid the company approximately \$23.0 million.

The exercise of this right to purchase the maximum number of additional shares under the terms of the investor rights agreement allows Genzyme to maintain its current ownership level of Alnylam common stock of approximately 12%.

Press Release

Genzyme Corporation (GENZ) Exercises Right To Increase Stake In Alnylam Pharmaceuticals (ALNY)

Genzyme Exercises its Right to Purchase Additional Shares of Alnylam Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Genzyme, a Sanofi company, has exercised its right to purchase 344,448 unregistered shares of Alnylam's common stock in accordance with the terms of an investor rights agreement between Alnylam and Genzyme, dated January 11, 2014. These shares became available for purchase by Genzyme as a result of Alnylam's issuance of shares of common stock to Merck in connection with Alnylam's acquisition of Sirna Therapeutics. Under the investor rights agreement, Genzyme has the right to purchase additional shares to maintain its

ownership percentage of the company's common stock. On March 25, 2014, Genzyme purchased these additional shares at a purchase price of \$66.88, the closing price of Alnylam's stock that day, and paid the company approximately \$23.0 million. The exercise of this right to purchase the maximum number of additional shares under the terms of the investor rights agreement allows Genzyme to maintain its current ownership level of Alnylam common stock of approximately 12%.

In January 2014, Alnylam and Genzyme formed a collaboration for the development and commercialization of RNAi therapeutics as genetic medicines. In partial consideration for the rights granted to Genzyme under the alliance and pursuant to the terms of a stock purchase agreement, Genzyme purchased 8,766,338 shares of newly issued Alnylam common stock at a purchase price of approximately \$80, and paid the company \$700.0 million in aggregate cash consideration.

"Our transformational alliance with Genzyme is off to a great start, and we look forward to a close strategic relationship for many years to come," said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam. "This additional investment in Alnylam represents a continued endorsement of their commitment to our collaborative efforts as we work together to develop and commercialize RNAi therapeutics as genetic medicines."

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Alnylam 5x15™" product strategy. Alnylam's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. These include: patisiran (ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR for the treatment of ATTR in patients with TTR cardiac amyloidosis, including familial amyloidotic cardiomyopathy (FAC) and senile systemic amyloidosis (SSA); ALN-AT3, an RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD); ALN-CC5, an RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic targeting aminolevulinic acid synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP); ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; ALN-AAT, an RNAi therapeutic targeting alpha-1-antitrypsin (AAT) for the treatment of AAT deficiency liver disease; ALN-TMP, an RNAi therapeutic targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting angiotensin-like 3 (ANGPTL3) for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs yet to be disclosed. As part of its "Alnylam 5x15" strategy, as updated in early 2014, the company expects to have six to seven genetic medicine product candidates in clinical development - including at least two programs in Phase 3 and five to six programs with human proof of concept - by the end of 2015. The company's demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascleptis, Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In January 2014, Alnylam agreed to acquire Sirna Therapeutics, a wholly owned subsidiary of Merck. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, the New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com.

Filing Data

Not available.

Contract

Not available.